APRIL in B-cell malignancies and autoimmunity

Results and Problems in Cell Differentiation

Volumn 49, Issue , 2009, Pages 161-182

  Kimberley, Fiona C ^a   Medema, Jan Paul ^a   Hahne, Michael ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; TNFSF13 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 71749090493     PISSN: 00801844     EISSN: 18610412     Source Type: Book Series    
DOI: 10.1007/400_2008_19     Document Type: Article

References (100)

1. Abe M, Kido S et al (2006) BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 20(7):1313-1315
2. Batten M, Groom J et al (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192(10):1453-1466
3. Belnoue E, Pihlgren M et al (2008) APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early life bone marrow stromal cells. Blood 111(5):2755-2764
4. Benson MJ, Dillon SR et al (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180(6):3655-3659
5. Bombardier C, Gladman DD et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630-640
6. Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18(5):263-275
7. Bossen C, Cachero TG et al (2008) TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111:1004-1012
8. Castigli E, Scott S et al (2004) Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 101(11):3903-3908
9. Castigli E, Wilson SA et al (2005a) TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201(1):35-39
10. Castigli E, Wilson SA et al (2005b) TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37(8):829-834
11. Chan FK, Chun HJ et al (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288(5475):2351-2354
12. Cheema GS, Roschke V et al (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44(6):1313-1319
13. Chiu A, Xu W et al (2007) Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 109(2):729-739
14. Courtenay JS, Dallman MJ et al (1980) Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283(5748):666-668
15. Craxton A, Magaletti D et al (2003) Macrophage- and dendritic cell - dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 101(11):4464-4471
16. Darce JR, Arendt BK et al (2007) Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 179(11):7276-7286
17. Deshayes F, Lapree G et al (2004) Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene 23(17):3005-3012
18. Dillon SR, Gross JA et al (2006) An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5(3):235-246
19. Endo T, Nishio M et al (2007) BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 109(2):703-710
20. Garibyan L, Lobito AA et al (2007) Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Invest 117(6):1550-1557
21. Groom J, Kalled SL et al (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109(1):59-68
22. Gross JA, Johnston J et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404(6781):995-999
23. Gross JA, Dillon SR et al (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease impaired B cell maturation in mice lacking BLyS. Immunity 15(2):289-302
24. Hahne M, Kataoka T et al (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188(6):1185-1190
25. Haiat S, Billard C et al (2006) Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 118(3):281-292
26. Hardenberg G, Fernandez L et al (2008) APRIL facilitates viral-induced erythroleukemia but is dispensable for T cell immunity and lymphomagenesis. J Leukoc Biol 84(2):380-388. Epub 2008 May15
27. Hardenberg G, Planelles L et al (2007) Specific TLR ligands regulate APRIL secretion by dendritic cells in a PKR-dependent manner. Eur J Immunol 37(10):2900-2911
28. Hatzoglou A, Roussel J et al (2000) TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 165(3):1322-1330
29. Hay EM, Bacon PA et al (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86(7):447-458
30. He B, Chadburn A et al (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 172(5):3268-3279
31. He B, Xu W et al (2007) Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26(6):812-826
32. Hendriks J, Planelles L et al (2005) Heparan sulfate proteoglycan binding promotes APRILinduced tumor cell proliferation. Cell Death Differ 12(6):637-648
33. Huard B, Schneider P et al (2001) T cell costimulation by the TNF ligand BAFF. J Immunol 167(11):6225-6231
34. Hymowitz SG, Patel DR et al (2005) Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem 280(8):7218-7227
35. Ingold K, Zumsteg A et al (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201(9):1375-1383
36. Jonsson H, Nived O et al (1986) Symptomatic secondary Sjogren's syndrome in patients with systemic lupus erythematosus (SLE). Relation to anti-SS-A and anti-SS-B autoantibodies. Scand J Rheumatol Suppl 61:166-169
37. Kawasaki A, Tsuchiya N et al (2007) Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese. Rheumatology (Oxford) 46(5):776-782
38. Kelly K, Manos E et al (2000) APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 60(4):1021-1027
39. Kern C, Cornuel JF et al (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103(2):679-688
40. Kipps TJ (1997) Signal transduction pathways and mechanisms of apoptosis in CLL B-lymphocytes: their role in CLL pathogenesis. Hematol Cell Ther 39(Suppl 1):S17-S27
41. Knight AK, Radigan L et al (2007) High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol 124(2):182-189
42. Kolb JP, Kern C et al (2003) Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 3(4):261-286
43. Kolfschoten GM, Pradet-Balade B et al (2003) TWE-PRIL; a fusion protein of TWEAK and APRIL. Biochem Pharmacol 66(8):1427-1432
44. Koyama T, Tsukamoto H et al (2005) Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 64(7):1065-1067
45. Lee YH, Ota F et al (2007) APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility. Rheumatology (Oxford) 46(8):1274-1276
46. Litinskiy MB, Nardelli B et al (2002) DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3(9):822-829
47. Liu W, Szalai A et al (2004) Control of spontaneous B lymphocyte autoimmunity with adenovirusencoded soluble TACI. Arthritis Rheum 50(6):1884-1896
48. Lopez-Fraga M, Fernandez R et al (2001) Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2(10):945-951
49. Mackay F, Woodcock SA et al (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190(11):1697-1710
50. Maddison PJ (1999) Autoantibodies in SLE. Disease associations. Adv Exp Med Biol 455:141-145
51. Marsters SA, Yan M et al (2000) Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10(13):785-788
52. Mhawech-Fauceglia P, Kaya G et al (2006) The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 80(4):697-704
53. Moreaux J, Legouffe E et al (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8):3148-3157
54. Moreaux J, Cremer FW et al (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106(3):1021-1030
55. Moy FJ, Safran M et al (1997) Properly oriented heparin-decasaccharide- induced dimers are the biologically active form of basic fibroblast growth factor. Biochemistry 36(16):4782-4791
56. Nagatani K, Itoh K et al (2007) Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL. Arthritis Rheum 56(11):3554-3563
57. Ng LG, Sutherland AP et al (2004) B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 173(2):807-817
58. Nishio M, Endo T et al (2005) Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 106(3):1012-1020
59. Novak AJ, Bram RJ et al (2002a) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100(8):2973-2979
60. Novak U, Oppliger Leibundgut E et al (2002b) A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL). Blood 100(5):1787-1794
61. O'Connor BP, Raman VS et al (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199(1):91-98
62. Pelekanou V, Kampa M et al (2008) Expression of TNF-superfamily members BAFF and APRIL in breast cancer: Immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer 8(1):76
63. Planelles L, Carvalho-Pinto CE et al (2004) APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6(4):399-408
64. Planelles L, Castillo-Gutierrez S et al (2007) APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 92(9):1284-1285
65. Pradet-Balade B, Medema JP et al (2002) An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. Embo J 21(21):5711-5720
66. Ramanujam M, Wang X et al (2004) Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 173(5):3524-3534
67. Ramanujam M, Wang X et al (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116(3):724-734
68. Rennert P, Schneider P et al (2000) A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 192(11):1677-1684
69. Roschke V, Sosnovtseva S et al (2002) BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169(8):4314-4321
70. Roth W, Wagenknecht B et al (2001) APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ 8(4):403-410
71. Salzer U, Birmelin J et al (2007) Sequence analysis of TNFRSF13b, encoding TACI, in patients with systemic lupus erythematosus. J Clin Immunol 27(4):372-377
72. Salzer U, Chapel HM et al (2005) Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37(8):820-828
73. Schiemann B, Gommerman JL et al (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293(5537):2111-2114
74. Schwaller J, Schneider P et al (2007) Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 109(1):331-338
75. Seyler TM, Park YW et al (2005) BLyS and APRIL in rheumatoid arthritis. J Clin Invest 115(11):3083-3092
76. Siegel RM, Frederiksen JK et al (2000) Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288(5475):2354-2357
77. Stein JV, Lopez-Fraga M et al (2002) APRIL modulates B and T cell immunity. J Clin Invest 109(12):1587-1598
78. Stohl W (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets 6(4):351-358
79. Stohl W, Metyas S et al (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48(12):3475-3486
80. Stohl W, Metyas S et al (2004) Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 63(9):1096-1103
81. Stohl W, Xu D et al (2005) BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 52(7):2080-2091
82. Tan SM, Xu D et al (2003) Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48(4):982-992
83. Tezuka H, Abe Y et al (2007) Regulation of IgA production by naturally occurring TNF/iNOSproducing dendritic cells. Nature 448(7156):929-933
84. Thompson JS, Bixler SA et al (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293(5537):2108-2111
85. Thompson JS, Schneider P et al (2000) BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 192(1):129-135
86. Vallerskog T, Heimburger M et al (2006) Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8(6):R167
87. Varfolomeev E, Kischkel F et al (2004) APRIL-deficient mice have normal immune system development. Mol Cell Biol 24(3):997-1006
88. von Bulow GU, Russell H et al (2000) Molecular cloning and functional characterization of murine transmembrane activator and CAML interactor (TACI) with chromosomal localization in human and mouse. Mamm Genome 11(8):628-632
89. von Bulow GU, van Deursen JM et al (2001) Regulation of the T-independent humoral response by TACI. Immunity 14(5):573-582
90. Wallweber HJ, Compaan DM et al (2004) The crystal structure of a proliferation-inducing ligand, APRIL. J Mol Biol 343(2):283-290
91. Wang H, Marsters SA et al (2001) TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2(7):632-637
92. Weyand CM, Kang YM et al (2003) The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curr Opin Rheumatol 15(3):259-266
93. Wu Y, Bressette D et al (2000) Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 275(45):35478-35485
94. Xia XZ, Treanor J et al (2000) TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 192(1):137-143
95. Xu S, Lam KP (2001) B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 21(12):4067-4074
96. Yan M, Brady JR et al (2001a) Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 11(19):1547-1552
97. Yan M, Wang H et al (2001b) Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2(7):638-643
98. Yang M, Hase H et al (2005) B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol 175(5):2814-2824
99. Yu G, Boone T et al (2000) APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 1(3):252-256
100. Zhang J, Roschke V et al (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166(1):6-10